Accent Therapeutics, Inc.

Accent Therapeutics is a biopharmaceutical company dedicated to developing a new class of small molecule precision cancer therapies. They take a novel approach to cancer treatment by targeting critical intracellular dependencies that are common across multiple cancer types. Their expertise lies in RNA-modifying proteins (RMPs) and they have built a flexible model that allows them to develop potentially transformative biomarker-driven cancer medicines.

Accent's therapies are designed to address both novel and known, but suboptimally-addressed, high-impact oncology targets. Their goal is to benefit large patient populations with significant unmet medical needs. They have several lead programs in development, including a first-in-class DHX9 inhibitor and a potential best-in-class inhibitor for KIF18A. They are actively conducting IND-enabling studies for both of these programs.

Accent Therapeutics offers a comprehensive benefits package that includes a strong focus on work-life balance. Employees enjoy 15 days of paid time off, plus wellness days and floating holidays. The company also provides a winter shutdown and summer hours, as well as generous parental leave and sick time.

Accent Therapeutics offers a comprehensive benefits package designed to support employees and their families. This includes health insurance plans, flexible spending programs, an onsite meditation/yoga room, life and disability insurance, a 401k program, an employee assistance program, 15 days of PTO plus wellness days and floating holidays, winter shutdown and summer hours, generous parental leave and sick time, employee referral and recognition programs, a transportation program, and weekly lunches and a stocked kitchen.

Accent Therapeutics is a biopharmaceutical company dedicated to developing a new class of precision cancer therapies. They are leveraging their expertise in RNA-modifying protein (RMP) biology to identify and exploit critical intracellular dependencies that span multiple types of cancer. Their goal is to create small molecule therapeutics that inhibit these targets and offer far-reaching potential for patients with significant unmet medical needs.

Accent Therapeutics cultivates a culture that prioritizes collaboration, innovation, and a deep commitment to improving patient outcomes in the fight against cancer. They value a diverse and experienced team of "ACCENTuators" united by a sense of purpose, rigor, patient focus, and a contagious enthusiasm for pushing boundaries in scientific research. This culture fosters an environment of adventurous spirits who work together to translate extraordinary science into life-changing therapeutics for patients living with cancer.

Accent Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace where everyone feels valued, respected, and empowered to contribute their unique perspectives and talents. They believe that a diverse workforce is essential to their success and that by embracing a culture of inclusivity, they can attract and retain top talent, drive innovation, and make a positive impact on the lives of patients living with cancer.